TLX · Nasdaq, OTC · CIK 0002007191

Telix Pharmaceuticals Ltd

Telix Pharmaceuticals Ltd’s most recent SEC filing in our snapshot is a Form 6-K filed on Oct 21, 2026. In fiscal 2025 (year ended Dec 31, 2025) it reported revenue of $803.8M and net income of -$7.1M, according to its XBRL data on EDGAR. Its EDGAR record lists 3 Form 4 insider filings from the 12 months before our last refresh.

SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.

Revenue, FY2025
$803.8M
Net income, FY2025
-$7.1M
Form 4 filings on record, past 12 months
3

Company overview

Legal name (as filed)
Telix Pharmaceuticals Ltd
Tickers
TLX, TLPPF
SEC Central Index Key (CIK)
0002007191
Industry (SIC)
Pharmaceutical Preparations (code 2834)
Business address
NORTH MELBOURNE, Australia
State or country of incorporation
Australia
Fiscal year ends
December 31
SEC filer category
Large accelerated filer
Position in SEC ticker list
#1661 of the 3,000 companies we track

Five-year financial highlights

Full-year figures from Telix Pharmaceuticals Ltd’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in U.S. dollars; the fiscal year is named for the calendar year in which it ends.

Revenue
$333.0MFY2023$516.6MFY2024$803.8MFY2025
Net income
$4.2MFY2023$33.7MFY2024-$7.1MFY2025
TLX annual results
ItemFY2023
ended Dec 31, 2023		FY2024
ended Dec 31, 2024		FY2025
ended Dec 31, 2025
Revenue$333.0M$516.6M$803.8M
Net income$4.2M$33.7M-$7.1M
Diluted EPS$0.01$0.10-$0.02
Total assets$277.3M$940.4M$1.2B
Cash and equivalents$84.3M$440.0M$141.9M

XBRL tags used: revenue = Revenue; netIncome = ProfitLoss; assets = Assets; eps = DilutedEarningsLossPerShare; cash = CashAndCashEquivalents. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.

How to read these numbers

Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.

Latest key reports

The most recent filing of each major report type, even if it falls outside the 40 newest filings below.

TLX latest annual, quarterly, current and proxy reports
FiledFormWhat it isOriginal
Feb 20, 202620-FAnnual report of a foreign private issuer· period Dec 31, 2025Document · Index
Oct 21, 20266-KReport of a foreign private issuer· period Oct 21, 2026Document · Index

Recent SEC filings

The 40 newest documents filed by or about Telix Pharmaceuticals Ltd, by form type:

6-K ×223 ×104 ×3UPLOAD ×2CORRESP ×120-F/A ×1F-3ASR ×1
TLX recent filings
FiledFormWhat it isOriginal
Oct 21, 20266-KReport of a foreign private issuer· period Oct 21, 2026Document · Index
Sep 30, 20266-KReport of a foreign private issuer· period Sep 30, 2026Document · Index
Sep 21, 20266-KReport of a foreign private issuer· period Sep 21, 2026Document · Index
Sep 14, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 7, 2026Document · Index
Sep 14, 20266-KReport of a foreign private issuer· period Sep 14, 2026Document · Index
Sep 2, 20266-KReport of a foreign private issuer· period Sep 2, 2026Document · Index
Sep 1, 20266-KReport of a foreign private issuer· period Sep 1, 2026Document · Index
Aug 20, 20266-KReport of a foreign private issuer· period Jun 30, 2026Document · Index
Jul 21, 20266-KReport of a foreign private issuer· period Jun 30, 2026Document · Index
Jul 2, 20266-KReport of a foreign private issuer· period Jul 1, 2026Document · Index
May 21, 20266-KCURRENT REPORT OF FOREIGN ISSUER PURSUANT TO RULES 13A-16 AND 15D-16 AMENDMENTS· period May 20, 2025Document · Index
May 18, 20263Initial statement of beneficial ownership· period May 11, 2026Document · Index
May 18, 20263Initial statement of beneficial ownership· period May 11, 2026Document · Index
May 18, 20263Initial statement of beneficial ownership· period May 11, 2026Document · Index
May 6, 20264Statement of changes in beneficial ownership (insider trade)· period Apr 28, 2026Document · Index
Apr 23, 20266-KCURRENT REPORT OF FOREIGN ISSUER PURSUANT TO RULES 13A-16 AND 15D-16 AMENDMENTS· period Apr 22, 2026Document · Index
Apr 23, 2026UPLOADUPLOADDocument · Index
Apr 21, 20266-KCURRENT REPORT OF FOREIGN ISSUER PURSUANT TO RULES 13A-16 AND 15D-16 AMENDMENTS· period Apr 20, 2026Document · Index
Apr 20, 20266-KCURRENT REPORT OF FOREIGN ISSUER PURSUANT TO RULES 13A-16 AND 15D-16 AMENDMENTS· period Apr 19, 2026Document · Index
Apr 17, 2026CORRESPCORRESPDocument · Index
Apr 14, 20266-KReport of a foreign private issuer· period Apr 14, 2026Document · Index
Apr 14, 20266-KReport of a foreign private issuer· period Apr 14, 2026Document · Index
Apr 13, 20266-KCURRENT REPORT OF FOREIGN ISSUER PURSUANT TO RULES 13A-16 AND 15D-16 AMENDMENTS· period Apr 12, 2026Document · Index
Apr 10, 20266-KReport of a foreign private issuer· period Apr 9, 2026Document · Index
Apr 9, 20266-KReport of a foreign private issuer· period Apr 9, 2026Document · Index
Apr 7, 20266-KReport of a foreign private issuer· period Mar 31, 2026Document · Index
Apr 3, 2026UPLOADUPLOADDocument · Index
Apr 2, 20266-KCURRENT REPORT OF FOREIGN ISSUER PURSUANT TO RULES 13A-16 AND 15D-16 AMENDMENTS· period Apr 1, 2026Document · Index
Apr 1, 20264Statement of changes in beneficial ownership (insider trade)· period Mar 29, 2026Document · Index
Apr 1, 20263Initial statement of beneficial ownership· period Mar 18, 2026Document · Index
Apr 1, 20263Initial statement of beneficial ownership· period Mar 18, 2026Document · Index
Apr 1, 20263Initial statement of beneficial ownership· period Mar 18, 2026Document · Index
Apr 1, 20263Initial statement of beneficial ownership· period Mar 18, 2026Document · Index
Mar 20, 202620-F/AAnnual report of a foreign private issuer· period Dec 31, 2025Document · Index
Mar 18, 20263Initial statement of beneficial ownership· period Mar 18, 2026Document · Index
Mar 18, 20263Initial statement of beneficial ownership· period Mar 18, 2026Document · Index
Mar 18, 20263Initial statement of beneficial ownership· period Mar 18, 2026Document · Index
Mar 16, 20266-KCURRENT REPORT OF FOREIGN ISSUER PURSUANT TO RULES 13A-16 AND 15D-16 AMENDMENTS· period Mar 15, 2026Document · Index
Mar 10, 20266-KCURRENT REPORT OF FOREIGN ISSUER PURSUANT TO RULES 13A-16 AND 15D-16 AMENDMENTS· period Mar 9, 2026Document · Index
Feb 20, 2026F-3ASRF-3ASRDocument · Index

Insider filing activity

3 Form 4 filings appear in Telix Pharmaceuticals Ltd’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.

Other companies in Pharmaceutical Preparations

All 194 companies in Pharmaceutical Preparations

On Amazon

Popular tools for investors

As an Amazon Associate I earn from qualifying purchases.

Electronics Plaud Note Pro AI Voice Recorder An AI voice recorder that turns earnings calls and meetings into notes. View on Amazon → Electronics Amazon Kindle Paperwhite Signature Edition 32GB Read investing classics and long reports without eye strain. View on Amazon → Electronics Apple 2026 MacBook Air 13-inch Laptop A lightweight laptop for spreadsheets and filing research. View on Amazon →

Source

  • U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0002007191 and XBRL company facts. Telix Pharmaceuticals Ltd on EDGAR.
  • Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.

Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.